药监总局加强中药提取监管 勒令不达标药企停产

2016-01-05 佚名 中新网

针对中药提取环节存在的突出问题,国家食品药品监督管理总局于2014年7月印发了《关于加强中药生产中提取和提取物监督管理的通知》(食药监药化监〔2014〕135号,以下简称135号文件),明确了中药提取和提取物管理要求并规定了过渡期。自2016年1月1日起,凡不具备相应提取能力的中成药生产企业必须停止生产,生产使用中药提取物必须备案。 自2016年1月1日起,凡不具备相应提取能力的中成药生产企业必

针对中药提取环节存在的突出问题,国家食品药品监督管理总局于2014年7月印发了《关于加强中药生产中提取和提取物监督管理的通知》(食药监药化监〔2014〕135号,以下简称135号文件),明确了中药提取和提取物管理要求并规定了过渡期。自2016年1月1日起,凡不具备相应提取能力的中成药生产企业必须停止生产,生产使用中药提取物必须备案。

自2016年1月1日起,凡不具备相应提取能力的中成药生产企业必须停止生产。各省(区、市)食品药品监督管理局要按照135号文件的要求,停止批准中药提取委托加工。对于已经批准的中药提取委托加工,要求药品生产企业必须从2016年1月1日起停止委托提取。对于不具备中药前处理和提取能力的中成药生产企业,自2016年1月1日起,停止相应中药品种的生产。逾期不停止生产的,食品药品监督管理部门依据《中华人民共和国药品管理法》(2015年修订,下同)第七十八条规定严肃查处。

自2016年1月1日起,生产使用中药提取物必须备案。自2016年1月1日起,对中成药国家药品标准处方项下载明,且具有单独国家药品标准的中药提取物实施备案管理。凡生产或使用上述中药提取物的企业,都必须按照《中药提取物备案管理实施细则》(见135号文件附件)在各省(区、市)食品药品监督管理局备案。凡是违反规定、使用未备案的中药提取物投料生产中成药的,各省(区、市)食品药品监督管理局依据《中华人民共和国药品管理法》第七十八条规定严肃查处。

各省(区、市)食品药品监督管理局要按照135号文件第七条及其附件第二条的要求,严格审查备案中药提取物的范围,对不属于备案范围的不予备案;已经备案的必须取消。

加强监督检查。各省(区、市)食品药品监督管理局要加强监督检查,落实监管责任,确保上述应停产企业按时停产。对检查发现的违法违规行为要坚决依法查处,并及时向社会公开。凡不具备中药提取能力的中成药生产企业,不得换发《药品生产许可证》(或相应生产范围);对单独生产中药提取物的企业,不再核发《药品生产许可证》。国家食品药品监督管理总局将进一步加大飞行检查、跟踪检查的力度和频次,对违法违规生产行为严肃查处并予以曝光;对于把关不严、监管不力的地方,将予以通报批评,并严肃问责。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1840403, encodeId=d39c1840403d1, content=<a href='/topic/show?id=186b8e937c6' target=_blank style='color:#2F92EE;'>#药监总局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87937, encryptionId=186b8e937c6, topicName=药监总局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Sep 29 21:16:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797119, encodeId=e7bb1e9711979, content=<a href='/topic/show?id=b17e22468f1' target=_blank style='color:#2F92EE;'>#中药提取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22468, encryptionId=b17e22468f1, topicName=中药提取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Sep 15 16:16:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56630, encodeId=d0ea566306b, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56631, encodeId=7c80566312d, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56632, encodeId=fc2256632e6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56633, encodeId=e497566337c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56634, encodeId=e8385663454, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56635, encodeId=804056635aa, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371437, encodeId=317213e1437b4, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 07 00:16:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52174, encodeId=6fb0521e42a, content=是该查一查了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Tue Jan 05 14:59:00 CST 2016, time=2016-01-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1840403, encodeId=d39c1840403d1, content=<a href='/topic/show?id=186b8e937c6' target=_blank style='color:#2F92EE;'>#药监总局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87937, encryptionId=186b8e937c6, topicName=药监总局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Sep 29 21:16:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797119, encodeId=e7bb1e9711979, content=<a href='/topic/show?id=b17e22468f1' target=_blank style='color:#2F92EE;'>#中药提取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22468, encryptionId=b17e22468f1, topicName=中药提取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Sep 15 16:16:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56630, encodeId=d0ea566306b, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56631, encodeId=7c80566312d, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56632, encodeId=fc2256632e6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56633, encodeId=e497566337c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56634, encodeId=e8385663454, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56635, encodeId=804056635aa, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371437, encodeId=317213e1437b4, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 07 00:16:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52174, encodeId=6fb0521e42a, content=是该查一查了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Tue Jan 05 14:59:00 CST 2016, time=2016-01-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1840403, encodeId=d39c1840403d1, content=<a href='/topic/show?id=186b8e937c6' target=_blank style='color:#2F92EE;'>#药监总局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87937, encryptionId=186b8e937c6, topicName=药监总局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Sep 29 21:16:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797119, encodeId=e7bb1e9711979, content=<a href='/topic/show?id=b17e22468f1' target=_blank style='color:#2F92EE;'>#中药提取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22468, encryptionId=b17e22468f1, topicName=中药提取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Sep 15 16:16:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56630, encodeId=d0ea566306b, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56631, encodeId=7c80566312d, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56632, encodeId=fc2256632e6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56633, encodeId=e497566337c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56634, encodeId=e8385663454, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56635, encodeId=804056635aa, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371437, encodeId=317213e1437b4, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 07 00:16:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52174, encodeId=6fb0521e42a, content=是该查一查了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Tue Jan 05 14:59:00 CST 2016, time=2016-01-05, status=1, ipAttribution=)]
    2016-01-13 medsic

    对,

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1840403, encodeId=d39c1840403d1, content=<a href='/topic/show?id=186b8e937c6' target=_blank style='color:#2F92EE;'>#药监总局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87937, encryptionId=186b8e937c6, topicName=药监总局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Sep 29 21:16:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797119, encodeId=e7bb1e9711979, content=<a href='/topic/show?id=b17e22468f1' target=_blank style='color:#2F92EE;'>#中药提取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22468, encryptionId=b17e22468f1, topicName=中药提取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Sep 15 16:16:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56630, encodeId=d0ea566306b, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56631, encodeId=7c80566312d, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56632, encodeId=fc2256632e6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56633, encodeId=e497566337c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56634, encodeId=e8385663454, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56635, encodeId=804056635aa, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371437, encodeId=317213e1437b4, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 07 00:16:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52174, encodeId=6fb0521e42a, content=是该查一查了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Tue Jan 05 14:59:00 CST 2016, time=2016-01-05, status=1, ipAttribution=)]
    2016-01-13 medsic

    对,

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1840403, encodeId=d39c1840403d1, content=<a href='/topic/show?id=186b8e937c6' target=_blank style='color:#2F92EE;'>#药监总局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87937, encryptionId=186b8e937c6, topicName=药监总局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Sep 29 21:16:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797119, encodeId=e7bb1e9711979, content=<a href='/topic/show?id=b17e22468f1' target=_blank style='color:#2F92EE;'>#中药提取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22468, encryptionId=b17e22468f1, topicName=中药提取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Sep 15 16:16:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56630, encodeId=d0ea566306b, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56631, encodeId=7c80566312d, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56632, encodeId=fc2256632e6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56633, encodeId=e497566337c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56634, encodeId=e8385663454, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56635, encodeId=804056635aa, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371437, encodeId=317213e1437b4, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 07 00:16:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52174, encodeId=6fb0521e42a, content=是该查一查了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Tue Jan 05 14:59:00 CST 2016, time=2016-01-05, status=1, ipAttribution=)]
    2016-01-13 medsic

    good

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1840403, encodeId=d39c1840403d1, content=<a href='/topic/show?id=186b8e937c6' target=_blank style='color:#2F92EE;'>#药监总局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87937, encryptionId=186b8e937c6, topicName=药监总局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Sep 29 21:16:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797119, encodeId=e7bb1e9711979, content=<a href='/topic/show?id=b17e22468f1' target=_blank style='color:#2F92EE;'>#中药提取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22468, encryptionId=b17e22468f1, topicName=中药提取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Sep 15 16:16:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56630, encodeId=d0ea566306b, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56631, encodeId=7c80566312d, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56632, encodeId=fc2256632e6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56633, encodeId=e497566337c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56634, encodeId=e8385663454, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56635, encodeId=804056635aa, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371437, encodeId=317213e1437b4, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 07 00:16:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52174, encodeId=6fb0521e42a, content=是该查一查了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Tue Jan 05 14:59:00 CST 2016, time=2016-01-05, status=1, ipAttribution=)]
    2016-01-13 medsic

    good

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1840403, encodeId=d39c1840403d1, content=<a href='/topic/show?id=186b8e937c6' target=_blank style='color:#2F92EE;'>#药监总局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87937, encryptionId=186b8e937c6, topicName=药监总局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Sep 29 21:16:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797119, encodeId=e7bb1e9711979, content=<a href='/topic/show?id=b17e22468f1' target=_blank style='color:#2F92EE;'>#中药提取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22468, encryptionId=b17e22468f1, topicName=中药提取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Sep 15 16:16:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56630, encodeId=d0ea566306b, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56631, encodeId=7c80566312d, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56632, encodeId=fc2256632e6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56633, encodeId=e497566337c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56634, encodeId=e8385663454, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56635, encodeId=804056635aa, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371437, encodeId=317213e1437b4, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 07 00:16:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52174, encodeId=6fb0521e42a, content=是该查一查了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Tue Jan 05 14:59:00 CST 2016, time=2016-01-05, status=1, ipAttribution=)]
    2016-01-13 medsic

    不错的决定……

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1840403, encodeId=d39c1840403d1, content=<a href='/topic/show?id=186b8e937c6' target=_blank style='color:#2F92EE;'>#药监总局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87937, encryptionId=186b8e937c6, topicName=药监总局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Sep 29 21:16:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797119, encodeId=e7bb1e9711979, content=<a href='/topic/show?id=b17e22468f1' target=_blank style='color:#2F92EE;'>#中药提取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22468, encryptionId=b17e22468f1, topicName=中药提取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Sep 15 16:16:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56630, encodeId=d0ea566306b, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56631, encodeId=7c80566312d, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56632, encodeId=fc2256632e6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56633, encodeId=e497566337c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56634, encodeId=e8385663454, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56635, encodeId=804056635aa, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371437, encodeId=317213e1437b4, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 07 00:16:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52174, encodeId=6fb0521e42a, content=是该查一查了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Tue Jan 05 14:59:00 CST 2016, time=2016-01-05, status=1, ipAttribution=)]
    2016-01-13 medsic

    不错的决定……

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1840403, encodeId=d39c1840403d1, content=<a href='/topic/show?id=186b8e937c6' target=_blank style='color:#2F92EE;'>#药监总局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87937, encryptionId=186b8e937c6, topicName=药监总局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Sep 29 21:16:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797119, encodeId=e7bb1e9711979, content=<a href='/topic/show?id=b17e22468f1' target=_blank style='color:#2F92EE;'>#中药提取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22468, encryptionId=b17e22468f1, topicName=中药提取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Sep 15 16:16:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56630, encodeId=d0ea566306b, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56631, encodeId=7c80566312d, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56632, encodeId=fc2256632e6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56633, encodeId=e497566337c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56634, encodeId=e8385663454, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56635, encodeId=804056635aa, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371437, encodeId=317213e1437b4, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 07 00:16:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52174, encodeId=6fb0521e42a, content=是该查一查了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Tue Jan 05 14:59:00 CST 2016, time=2016-01-05, status=1, ipAttribution=)]
    2016-01-07 zhouqu_8
  10. [GetPortalCommentsPageByObjectIdResponse(id=1840403, encodeId=d39c1840403d1, content=<a href='/topic/show?id=186b8e937c6' target=_blank style='color:#2F92EE;'>#药监总局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87937, encryptionId=186b8e937c6, topicName=药监总局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Sep 29 21:16:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797119, encodeId=e7bb1e9711979, content=<a href='/topic/show?id=b17e22468f1' target=_blank style='color:#2F92EE;'>#中药提取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22468, encryptionId=b17e22468f1, topicName=中药提取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Sep 15 16:16:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56630, encodeId=d0ea566306b, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56631, encodeId=7c80566312d, content=对,, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56632, encodeId=fc2256632e6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56633, encodeId=e497566337c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56634, encodeId=e8385663454, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56635, encodeId=804056635aa, content=不错的决定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 10:42:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371437, encodeId=317213e1437b4, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 07 00:16:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52174, encodeId=6fb0521e42a, content=是该查一查了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/e3b78fdf1c4d3e2e9ec6e03f643df0e2/6ca494c7b27a25fdde0721c5dac778d7.jpg, createdBy=2e441664544, createdName=鲜花飞鸟, createdTime=Tue Jan 05 14:59:00 CST 2016, time=2016-01-05, status=1, ipAttribution=)]
    2016-01-05 鲜花飞鸟

    是该查一查了

    0

相关资讯

临床严格自查埋单:乱象丛生,“坦白从宽”?

7月22日,根据国务院“最严谨的标准、最严格的监管、最严厉的处罚、最严肃的问责”要求,国家食药监总局(CFDA)发布了“关于开展药物临床试验数据自查核查工作”的117公告,并附以1622个药物临床试验数据自查核查品种清单,提交截止时间是8月25日。 不难想象,在“史上最严药物临床试验数据自查令”下达之后相关制药企业的集体慌乱状态。措手不及的不只是制药企业,还有围绕药物临床试验的CRO、药物临

CFDA发布关于药物临床试验数据自查情况的公告

按照国家食品药品监督管理总局《关于开展药物临床试验数据自查核查工作的公告》(2015年第117号)要求,药物临床试验数据自查和报告工作于2015年8月25日24时结束。现将自查结果公告如下: 一、本次药物临床试验自查涉及1622个品种。其中,申请人提交自查资料的注册申请为1094个,占 67%;主动撤回的注册申请317个,占20%;申请减免临床试验等不需要提交的注册申请193个,占12%。 二

CFDA拟推60天快速审批抗肿瘤创新药物临床研究申请

药物审批是所有医药开发者最为头痛的环节。而在中国,医药审批较为繁琐的过程也广为医药产业人士诟病。然而2015年来,中国医药相关部门的一系列举措似乎将要改变这一现象。最近,有消息人士透露中国CFDA正考虑以抗肿瘤药物为试点,推行临床试验新药(IND)60天内快速审批的政策。如果属实,中国将成为继新加坡、韩国之后第三个对临床早期研究进行快速审批的亚洲国家。 产业方面消息人士表示,CFDA下属的药

食品药品监督管理总局曝光8起虚假宣传广告

国家食品药品监督管理总局9月3日通告,近期,食品药品监管部门监测到4个药品和4个保健食品擅自发布含有夸大宣传治愈率或有效率,利用患者的名义、形象做功效证明和承诺等问题的虚假广告,欺骗和误导消费者。具体通告情况如下:一、违法广告所涉企业及产品情况:(一)西安大唐制药集团有限公司生产的药品“醒脾开胃颗粒(广告中标示名称:大唐奥舒)”。该产品通过电视媒介发布违法广告,宣称“大唐奥舒用了效果就是不一样,一

CFDA全新发布:药品注册流程新规则

食品药品监管总局关于进一步规范药品注册受理工作的通知 食药监药化管〔2015〕122号 2015年07月30日 发布 各省、自治区、直辖市食品药品监督管理局: 为进一步规范药品注册受理工作,现印发《药品注册形式审查补充要求》(见附件),请遵照执行,并将有关要求通知如下: 一、各省级局应严格按照《药品注册管理办法》及相关规定,在5个工作日内完成对申报资料的形式审查,一次性告

9家网站涉嫌误导消费者遭CFDA曝光

近期,国家食品药品监管总局监督检查发现,9家互联网站违法发布虚假信息,内容含有不科学地宣称治疗疾病功效的断言,以及利用学术机构、专家、医生、患者等名义形象作证明等问题,欺骗误导消费者,危害公众饮食用药安全。现将有关情况通告如下: 一、发布虚假信息网站及产品情况: (一)标识“冬虫草蝮蛇胶囊官网”网站,发布的“冬虫草蝮蛇胶囊”产品信息,宣称“绿色、天然、无任何毒副作用;调节免疫系统、对抗风湿